LY3549492 for Obesity
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial focuses on testing the safety and tolerance of a new drug, LY3549492, for individuals who are overweight or have obesity. Researchers aim to observe how the drug behaves in the body when administered in multiple doses over approximately 8 weeks. The trial seeks participants with a body mass index (BMI) between 25 and 45 who do not have obesity due to specific endocrine disorders, such as Cushing's syndrome. Participants should also have stable blood pressure and heart health. As a Phase 1 trial, participants will be among the first to help researchers understand how this new treatment works in people.
Is there any evidence suggesting that LY3549492 is likely to be safe for humans?
Research shows that LY3549492 is under study to assess its safety and tolerability. Earlier studies examined healthy adults to understand the drug's effects in the body with repeated doses. Although detailed safety information from these studies isn't available yet, the early testing phase indicates that researchers are still gathering basic safety data. They closely monitor participants for any side effects or issues to ensure the drug's safety before advancing to more comprehensive testing.12345
Why do researchers think this study treatment might be promising?
Researchers are excited about LY3549492 for obesity because it offers a fresh approach by targeting biological pathways differently than current options like appetite suppressants or fat absorption blockers. While many existing treatments focus on managing caloric intake or fat absorption, LY3549492 works by engaging a novel mechanism that could potentially regulate metabolism more effectively. Its oral administration also promises convenience, which might improve adherence and outcomes for patients struggling with obesity.
What evidence suggests that LY3549492 might be an effective treatment for obesity?
Research has shown that LY3549492 is under study for its potential to address obesity and type 2 diabetes. It influences how the body processes sugar and fat, which might aid in weight control. Early results from similar treatments have demonstrated success in lowering blood sugar levels and promoting weight loss. While specific data for LY3549492 is not yet available, these promising early signs have sparked scientific interest in further investigation. Participants in this trial will receive LY3549492 in one of the treatment groups to evaluate its effectiveness.23567
Who Is on the Research Team?
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
Principal Investigator
Eli Lilly and Company
Are You a Good Fit for This Trial?
This study is for healthy adults who are overweight or have obesity. The trial will last about 8 weeks, and participants must meet specific health criteria to join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive multiple doses of LY3549492 to assess safety, tolerability, and pharmacokinetics
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- LY3549492
Find a Clinic Near You
Who Is Running the Clinical Trial?
Eli Lilly and Company
Lead Sponsor
Dr. Daniel Skovronsky
Eli Lilly and Company
Chief Medical Officer since 2018
MD from Harvard Medical School
David A. Ricks
Eli Lilly and Company
Chief Executive Officer since 2017
BSc from Purdue University, MBA from Indiana University